Depo-Provera Meningioma Lawyers Reappointed to MDL Leadership Roles

Lead attorneys in the MDL will continue to take actions that represent all women pursuing Depo-Provera lawsuits over the development of meningioma brain tumors, as they prepare for the first test trial in December 2026.

Just over a year after all federal Depo-Provera meningioma lawsuits were consolidated before one judge as part of a multidistrict litigation (MDL), a group of attorneys has been reappointed to continue serving the interests of all women who have filed claims alleging that the birth control injections caused them to develop brain tumors.

The litigation involves claims that Pfizer and other generic drug makers failed to adequately warn women about the risk of meningioma from Depo-Provera, which is a birth control injection introduced in 1992, which is designed to be administered once every three months. Over the last three decades, it has been heavily promoted as a safe and effective form of contraception, with tens of millions of women receiving the shots.

Concerns about Depo-Provera meningioma side effects emerged in April 2024, following the publication of a study warning that women receiving the birth control injections appeared to face a five-fold greater risk of developing brain tumors.

In the weeks that followed, a series of Depo-Provera brain tumor lawsuits began to be filed, as women started connecting their own diagnoses to years of receiving the “Depo shot.”

As lawsuits continued to be filed in courts across the United States, the growing number of federal cases were ultimately centralized last February for coordinated pretrial proceedings in the Northern District of Florida before U.S. District Judge M. Casey Rodgers. At that time, only 27 product liability lawsuits had been filed against Pfizer and generic manufacturers. However, one year later, the litigation has grown to include more than 3,000 claims.

Given the widespread use of the drug, Depo-Provera meningioma lawyers expect the litigation to continue expanding, as more women learn they may have developed brain tumors linked to the injections.

Upon assignment, Judge Rodgers quickly moved the litigation forward by selecting five “pilot” cases to be prepared for early bellwether trials, signaling an effort to efficiently evaluate key issues that will shape the broader proceedings.

These early trials are designed to show how juries may respond to the scientific evidence, expert testimony and legal arguments expected to be repeated throughout the litigation, despite differences in individual claims. The outcomes are expected to play a critical role in guiding potential settlement discussions in the Depo-Provera meningioma lawsuits.

To help manage the growing number of claims, Judge Rodgers also appointed a group Depo-Provera injury attorneys to serve in leadership roles last year, tasked with coordinating discovery and pretrial efforts on behalf of all women involved in the litigation.

In a court order (PDF) issued on March 20, approximately 70 attorneys were reappointed to continue serving in these leadership positions, citing the group’s effectiveness in advancing the litigation so far.

“The leadership work thus far has been exemplary, and the Court appreciates the efforts and interest of all attorneys who reapplied.”

– U.S. District Judge M. Casey Rodgers

The reappointed attorneys will continue to work on preparing the first bellwether lawsuits for trial, with the first Depo-Provera trial scheduled to begin on December 7, 2026. It will involve a lawsuit filed by Donna Toney of Florida, who alleges she suffered vertigo, dizziness and hearing loss due to a brain tumor caused by the birth control injections. Additional bellwether trials will follow in early 2027.

If the parties are unable to reach a global Depo-Provera brain tumor settlement after the bellwether process, Judge Rodgers could remand the remaining cases back to their original federal courts for individual trial dates.

To stay up to date on this litigation, sign up to receive Depo-Provera lawsuit updates sent directly to your inbox.